In a conversation with Pharmaceutical Executive, Gerren McHam, vice president of Government and External Affairs, API Innovation Center, discussed how China's recently updated export control regulations, along with broader geopolitical pressures, are exposing vulnerabilities in the U.S. pharmaceutical supply chain. Pharmaceutical Executive: How exposed is the U.S. pharmaceutical supply chain to China’s recently updated export control regulations? PE: How has the Strait of Hormuz situation shaped the API Innovation Center's thinking about geographic diversification? What we're doing at API Innovation Center is looking at how do geopolitical dynamics impact the supply chain? So, at the API Investment Center, we're looking at Metoprolol, we're looking at Albuterol, or Lorazepam just to give you an example.